A world leader
in scalp cooling
technology

Chemotherapy-induced hair loss is widely recognised as one of the most traumatic side effects associated with cancer treatment, and yet it is still often believed to be inevitable. Paxman are changing that.
Paxman's commitment to supporting patients goes beyond technological innovation; it's about fostering a holistic brand experience where patients are informed, connected, and empowered in their scalp cooling journey. As an investor, you're not just supporting a company; you're joining us in changing the face of cancer.
Explore more financial data →
What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →

Latest from Paxman

December 31, 2025

PAXMAN announces 510k Submission to the U.S. Food and Drug Administration (FDA) for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Read article →
November 24, 2025

Correction: Further updated Information on OPPS Reimbursement

Read article →
November 24, 2025

Correction: Updated Information on OPPS Reimbursement

Read article →
25+
years of pioneering scalp
cooling technology
65
countries worldwide
scalp cooling
100k+
cancer patients have scalp cooled across the world
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram